Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies

2010 ◽  
Vol 15 (4) ◽  
pp. 617-631 ◽  
Author(s):  
Thierry Poynard ◽  
Yen Ngo ◽  
Mona Munteanu ◽  
Dominique Thabut ◽  
Julien Massard ◽  
...  
2021 ◽  
Vol 164 ◽  
pp. 105404
Author(s):  
Hao Niu ◽  
Judith Sanabria-Cabrera ◽  
Ismael Alvarez-Alvarez ◽  
Mercedes Robles-Diaz ◽  
Simona Stankevičiūtė ◽  
...  

Heart ◽  
2018 ◽  
pp. heartjnl-2018-313955 ◽  
Author(s):  
Jennifer Susan Lees ◽  
Fiona A Chapman ◽  
Miles D Witham ◽  
Alan G Jardine ◽  
Patrick B Mark

ObjectivesVascular stiffness (VS) and vascular calcification (VC) are surrogate markers of vascular health associated with cardiovascular events. Vitamin K-dependent proteins (VKDP) are associated with VS and VC and require vitamin K for activity. We conducted a systematic review and meta-analysis of: (1) the effect of vitamin K supplementation on VS and VC and (2) association of inactive VKDP levels with incident cardiovascular disease and mortality.MethodsTwo authors searched MEDLINE and Embase databases and Cochrane and ISRCTN registries for studies of vitamin K clinical trials that measured effects on VC, VS or VKDP and longitudinal studies assessing effect of VKDP on incident CVD or mortality. Random effects meta-analyses were performed.ResultsThirteen controlled clinical trials (n=2162) and 14 longitudinal studies (n=10 726) met prespecified inclusion criteria. Vitamin K supplementation was associated with significant reduction in VC (−9.1% (95% CI −17.7 to −0.5); p=0.04) and VKDP (desphospho-uncarboxylated matrix Gla protein; −44.7% (95% CI −65.1 to −24.3), p<0.0001) and uncarboxylated osteocalcin; −12.0% (95% CI −16.7 to −7.2), p<0.0001) compared with control, with a non-significant improvement in VS. In longitudinal studies with median follow-up of 7.8 (IQR 4.9–11.3) years, VKDP levels were associated with a combined endpoint of CVD or mortality (HR 0.45 (95% CI 0.07 to 0.83), p=0.02).ConclusionsSupplementation with vitamin K significantly reduced VC, but not VS, compared with control. The conclusions drawn are limited by small numbers of studies with substantial heterogeneity. VKDP was associated with combined endpoint of CVD or mortality. Larger clinical trials of effect of vitamin K supplementation to improve VC, VS and long-term cardiovascular health are warranted.Trial registration numberCRD42017060344.


2020 ◽  
Author(s):  
Ying Dai ◽  
Jianghong Liu

Abstract Context Omega-3, a long-chain polyunsaturated fatty acid (LC-PUFA), may help promote healthy sleep outcomes. However, evidence from randomized controlled trials are inconclusive. Objective The objective of this systematic review and meta-analysis was to explore the impact of omega-3 LC-PUFA supplementation and related dietary intervention in clinical trials as well as omega-3 LC-PUFA exposure in longitudinal studies on human’s sleep-related outcome. Data Sources The PubMed, EMBASE, Cochrane Library, CINAHL, and AMED databases were searched from inception to November 2019. Randomized controlled trials, clinical trials that included a control group, and longitudinal studies that reported the intake of omega-3 LC-PUFA and sleep-related outcomes were included. Study Selection A total of 20 studies with 12 clinical trials and 8 longitudinal studies were identified for inclusion. Data Extraction Participant characteristics, study location, intervention information, and sleep-related outcome measurements were reported. Included studies were appraised with Cochrane risk-of-bias tools and the Newcastle-Ottawa Scale. Weighted mean differences (WMDs) and 95%CIs were pooled with fixed or random effect models. Results Omega-3 LC-PUFA may improve infants' sleep organization and maturity. It reduced the percentage of infants' active sleep (WMD = –8.40%; 95%CI, –14.50 to –2.29), sleep-wake transition (WMD = –1.15%; 95%CI, –2.09 to –0.20), and enhanced the percentage of wakefulness (WMD = 9.06%; 95%CI, 1.53–16.59) but had no effect on quiet sleep. Omega-3 reduced children’s total sleep disturbance score for those with clinical-level sleep problems (WMD = –1.81; 95%CI, –3.38 to –0.23) but had no effect on healthy children’s total sleep duration, sleep latency, or sleep efficiency. No effectiveness was found in adults’ total sleep duration, sleep latency, sleep efficiency, sleep quality, or insomnia severity. Conclusion Omega-3 LC-PUFA may improve certain aspects of sleep health throughout childhood. Additional robust studies are warranted to confirm the relationship between omega-3 LC-PUFA and sleep.


2018 ◽  
Vol 144 (4) ◽  
pp. 426-451 ◽  
Author(s):  
Kevin A. Hoff ◽  
Daniel A. Briley ◽  
Colin J. M. Wee ◽  
James Rounds

2018 ◽  
Vol 144 (10) ◽  
pp. 1045-1080 ◽  
Author(s):  
Ulrich Orth ◽  
Ruth Yasemin Erol ◽  
Eva C. Luciano

Sign in / Sign up

Export Citation Format

Share Document